Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Abbott Laboratories stock in Canada | $126.58

Own Abbott Laboratories shares in just a few minutes.

Abbott Laboratories
NYSE: ABT - USD
MEDICAL DEVICES
$126.58
- $0.14 ( - 0.11%)

Abbott Laboratories is a medical devices business based in the US. Abbott Laboratories stocks (ABT.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $127.44 – an increase of 6.07% over the previous week. Abbott Laboratories employs 109,000 staff and has a trailing 12-month revenue of around $42.3 billion.

How to buy shares in Abbott Laboratories

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ABT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Abbott Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Abbott Laboratories's stock price?

Since the stock market crash in March caused by coronavirus, Abbott Laboratories's stock price has had significant positive movement.

Its last market close was $126.58, which is 30.91% up on its pre-crash value of $87.45 and 105.45% up on the lowest point reached during the March crash when the stocks fell as low as $61.61.

If you had bought $1,000 worth of Abbott Laboratories stocks at the start of February 2020, those stocks would have been worth $721.80 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,454.40.

Abbott Laboratories stock price

Use our graph to track the performance of ABT stocks over time.

Abbott Laboratories shares at a glance

Information last updated 2021-10-22.
Latest market close$126.58
52-week range$101.56 - $129.20
50-day moving average $122.30
200-day moving average $119.57
Wall St. target price$137.05
PE ratio 31.2181
Dividend yield $1.8 (1.44%)
Earnings per share (TTM) $4.03

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
FREE TRADES
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get 2 free stocks when you open a Wealthsimple Trade personal account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
OFFER
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until December 31, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Abbott Laboratories price performance over time

Historical closes compared with the close of $126.58 from 2021-10-25

1 week (2021-10-15) N/A
1 month (2021-09-24) 1.78%
3 months (2021-07-26) 5.91%
6 months (2021-04-26) 3.26%
1 year (2020-10-23) 17.43%
2 years (2019-10-25) 55.03%
3 years (2018-10-25) 87.05%
5 years (2016-10-25) 214.95%

Is Abbott Laboratories under- or over-valued?

Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abbott Laboratories's P/E ratio

Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Abbott Laboratories shares trade at around 31x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Abbott Laboratories's PEG ratio

Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.8606. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Abbott Laboratories's EBITDA

Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.7 billion.

The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure a its profitability.

Abbott Laboratories financials

Revenue TTM $42.3 billion
Operating margin TTM 21.68%
Gross profit TTM $19.6 billion
Return on assets TTM 7.19%
Return on equity TTM 1987.64%
Profit margin 17.12%
Book value $19.07
Market capitalisation $223.1 billion

TTM: trailing 12 months

Shorting Abbott Laboratories shares

There are currently 11.2 million Abbott Laboratories shares held short by investors – that's known as Abbott Laboratories's "short interest". This figure is 9.7% up from 10.2 million last month.

There are a few different ways that this level of interest in shorting Abbott Laboratories shares can be evaluated.

Abbott Laboratories's "short interest ratio" (SIR)

Abbott Laboratories's "short interest ratio" (SIR) is the quantity of Abbott Laboratories shares currently shorted divided by the average quantity of Abbott Laboratories shares traded daily (recently around 4.7 million). Abbott Laboratories's SIR currently stands at 2.41. In other words for every 100,000 Abbott Laboratories shares traded daily on the market, roughly 2410 shares are currently held short.

However Abbott Laboratories's short interest can also be evaluated against the total number of Abbott Laboratories shares, or, against the total number of tradable Abbott Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abbott Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Abbott Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0065% of the tradable shares (for every 100,000 tradable Abbott Laboratories shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abbott Laboratories.

Abbott Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Abbott Laboratories's total ESG risk score

Total ESG risk: 32.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 01/01/2019) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Abbott Laboratories's environmental score

Environmental score: 3.98/100

Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Abbott Laboratories's social score

Social score: 20.71/100

Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Abbott Laboratories's governance score

Governance score: 13.15/100

Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Abbott Laboratories's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.

Abbott Laboratories share dividends

28%

Dividend payout ratio: 28.48% of net profits

Recently Abbott Laboratories has paid out, on average, around 28.48% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.44% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 1.44% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $1.8 per share.

While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.

Abbott Laboratories's most recent dividend payout was on 15 November 2021. The latest dividend was paid out to all shareholders who bought their shares by 14 October 2021 (the "ex-dividend date").

Have Abbott Laboratories's shares ever split?

Abbott Laboratories's shares were split on a 10000:4798 basis on 2 January 2013. So if you had owned 4798 shares the day before before the split, the next day you'd have owned 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.

Abbott Laboratories share price volatility

Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as $101.5601 up to $129.2004. A popular way to gauge a stock's volatility is its "beta".

ABT.US volatility(beta: 0.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.6714. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).

Abbott Laboratories overview

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. It has collaboration agreement with Cereno Scientific AB (publ).

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site